

# Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/S00F7937DF0EN.html

Date: March 2018 Pages: 46 Price: US\$ 125.00 (Single User License) ID: S00F7937DF0EN

## Abstracts

Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

#### Highlights

Synergy Pharmaceuticals Inc (Synergy Pharma) is a biopharmaceutical company that develops and commercializes new treatments for gastrointestinal (GI) diseases. The company pioneered its R&D efforts to develop its proprietary uroguanylin-based GI platform. It is also developing analogs of uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. The company's portfolio includes Trulance (plecanatide), which is structurally identical to uroguanylin, for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. Synergy Pharma's pipeline includes dolcanatide (SP-333), an investigational candidate under evaluation for the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc Key Recent Developments

Mar 01,2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update



and Business Update

Nov 09,2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results Oct 17,2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C) Aug 09,2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update May 10,2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.



Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



## Contents

#### **SECTION 1 - ABOUT THE COMPANY**

Synergy Pharmaceuticals Inc - Key Facts Synergy Pharmaceuticals Inc - Key Employees Synergy Pharmaceuticals Inc - Key Employee Biographies Synergy Pharmaceuticals Inc - Major Products and Services Synergy Pharmaceuticals Inc - History Synergy Pharmaceuticals Inc - Company Statement Synergy Pharmaceuticals Inc - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

#### **SECTION 2 – COMPANY ANALYSIS**

Company Overview Synergy Pharmaceuticals Inc - Business Description R&D Overview Synergy Pharmaceuticals Inc - Corporate Strategy Synergy Pharmaceuticals Inc - SWOT Analysis SWOT Analysis - Overview Synergy Pharmaceuticals Inc - Strengths Synergy Pharmaceuticals Inc - Weaknesses Synergy Pharmaceuticals Inc - Opportunities Synergy Pharmaceuticals Inc - Threats Synergy Pharmaceuticals Inc - Threats

#### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

#### SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES



Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Synergy Pharmaceuticals Inc, Recent Deals Summary

#### SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Mar 01, 2018: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update

Nov 09, 2017: Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results Oct 17, 2017: Synergy Pharmaceuticals Presents Results from Study Examining Patient and Physician Perceptions and Experiences with Irritable Bowel Syndrome with Constipation (IBS-C)

Aug 09, 2017: Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update

May 10, 2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update

Apr 17, 2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer

Mar 01, 2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update

#### **SECTION 6 – APPENDIX**

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



## **List Of Tables**

#### LIST OF TABLES

Synergy Pharmaceuticals Inc, Key Facts Synergy Pharmaceuticals Inc, Key Employees Synergy Pharmaceuticals Inc, Key Employee Biographies Synergy Pharmaceuticals Inc, Major Products and Services Synergy Pharmaceuticals Inc, History Synergy Pharmaceuticals Inc, Subsidiaries Synergy Pharmaceuticals Inc, Key Competitors Synergy Pharmaceuticals Inc, Ratios based on current share price Synergy Pharmaceuticals Inc, Annual Ratios Synergy Pharmaceuticals Inc, Annual Ratios (Cont...1) Synergy Pharmaceuticals Inc, Interim Ratios Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 Synergy Pharmaceuticals Inc, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios Efficiency Ratios



## **List Of Figures**

#### LIST OF FIGURES

Synergy Pharmaceuticals Inc, Performance Chart (2013 - 2017) 26 Synergy Pharmaceuticals Inc, Ratio Charts 28 Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29 Synergy Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

#### **COMPANIES MENTIONED**

Valeant Pharmaceuticals International Inc Takeda Pharmaceuticals America Inc Sucampo Pharmaceuticals Inc Shire Plc Ocera Therapeutics Inc Ironwood Pharmaceuticals Inc AstraZeneca Plc Allergan Plc



#### I would like to order

Product name: Synergy Pharmaceuticals Inc (SGYP) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/S00F7937DF0EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/S00F7937DF0EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970